Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mahuang Fuzi Decoction is a traditional Chinese medicine (TCM) herbal formula primarily composed of *Ephedra sinica* (Mahuang) and *Aconitum carmichaelii* (Fuzi), often with the addition of *Glycyrrhiza uralensis* (Gancao). It is traditionally used to treat syndromes characterized by Yang deficiency and exterior cold. In modern clinical research, specifically a study led by the Beijing Hospital of TCM (ChiCTR1900021485), it is being evaluated for the treatment of idiopathic membranous nephropathy (IMN) in patients categorized with Shaoyin-Taiyin syndrome according to Liujing syndrome differentiation. The formula is intended to reduce proteinuria and improve renal function by warming the yang, dispersing cold, and promoting diuresis to alleviate edema.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mahuang fuzi decoction.